SCHEMBL16616017

SCHEMBL16616017

CCOc1cc(-c2ccc(F)cc2F)ccc1C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.42
PIM3 Q86V86 1/20 0.42
ERN1 O75460 5/20 0.41
PTPRC P08575 1/20 0.41
LMNA P02545 2/20 0.40
KLKB1 P03952 1/20 0.40
ALDH1A1 P00352 3/20 0.39
MAPT P10636 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
DHFR P00374 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
TTR P02766 1/20 0.39
ALB P02768 1/20 0.39
HMGB1 P09429 1/20 0.39
HPGD P15428 1/20 0.39
CXCL12 P48061 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17535470 0.85 ERN1 (0.53) PIM1PIM3ERN1LMNAALDH1A1
SCHEMBL1881661 0.84 LMNA (0.50) ERN1LMNAALDH1A1MAPTKDM4E
SCHEMBL16616316 0.79 LMNA (0.48) LMNAALDH1A1MAPTKDM4EMEN1
SCHEMBL505574 0.78 PIM1 (0.50) PIM1PIM3ERN1LMNAALDH1A1
SCHEMBL18733829 0.77 LMNA (0.41) ERN1PTPRCLMNAALDH1A1MAPT
SCHEMBL19140557 0.76 ALDH1A1 (0.47) PIM1PIM3ERN1LMNAALDH1A1
SCHEMBL17535871 0.75 TDP1 (0.51) PTPRCLMNAKLKB1ALDH1A1KDM4E
SCHEMBL16616393 0.75 ALDH1A1 (0.39) LMNAALDH1A1KDM4EMEN1HPGD
SCHEMBL2599698 0.75 ERN1 (0.42) ERN1ALDH1A1MAPTMEN1HPGD
SCHEMBL16616319 0.75 PTGS1 (0.47) LMNAALDH1A1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055309-B1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) TAKEDA PHARMACEUTICALS CO (JP) 2018-06-13 EP disclosed
US-9751878-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 US disclosed
US-20160237087-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-18 US disclosed
EP-3055309-A1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) Takeda Pharmaceutical Company Limited (JP) 2016-08-17 EP disclosed
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
WO-2015052910-A1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 WO disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099777-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR4, SSTR2 PIM1 2984/4885PIM3 3362/4885ERN1 3408/4885
US-20160237087-A1 HETEROCYCLIC COMPOUNDS SSTR5, SSTR4, SSTR2 PIM1 2923/4885PIM3 3238/4885ERN1 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.